Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donafenib with Chemotherapy in Relapsed AML
NCT04402723Phase 1Terminated
- Sponsor
- Zelgen
- Start
- Nov 2018
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of donafenib in acute myeloid leukemia (AML) (2 arms), sponsored by Zelgen. Primary endpoint: Safety (including the type, severity and frequency of AE) at 2 months. Started Nov 2018; status: terminated.
02
Drugs
donafenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04402723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04402723.